Equities

Take Solutions Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Take Solutions Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)47.26
  • Today's Change-0.71 / -1.48%
  • Shares traded592.43k
  • 1 Year change+379.80%
  • Beta1.4808
Data delayed at least 15 minutes, as of Feb 18 2026 10:20 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Take Solutions Limited is an India-based contract research organization (CRO), which is engaged in supporting pharma, biotech and devices companies. The Company offers clients a combination of full-service clinical research, generics development, data sciences, regulatory affairs, and pharmacovigilance/safety services. Its range of services span from clinical trials to regulatory submissions to post-marketing safety, all backed by insights derived through proprietary industry network forums. Its digital healthcare services include medical decision-making (artificial intelligence and machine learning), and cloud adoption & mobility. Its global roster of clients includes large and small biopharmaceutical and device companies, United States federal agencies like Centers for Disease Control and Prevention (CDC) and the United States Department of Defense (DoD), as well as generics manufacturers. The Company's subsidiary is Ecron Acunova Limited.

  • Revenue in INR (TTM)0.00
  • Net income in INR36.61m
  • Incorporated2000
  • Employees2.00
  • Location
    Take Solutions LtdNo27Tank Bund Road, Nungambakkam, ChennaiCHENNAI 600034IndiaIND
  • Phone+91 4 466110700
  • Fax+91 4 445909009
  • Websitehttps://www.takesolutions.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Bioxyne Ltd1.83bn314.76m6.62bn16.0019.838.0318.123.620.00230.00230.01320.00572.166.3017.06--37.31-28.1755.76-38.1636.3235.9717.24-24.141.90--0.1125--204.8765.94138.29--127.89--
Arovella Therapeutics Ltd33.75m-482.25m6.74bn14.00--5.15--199.68-0.0067-0.00670.00050.01690.0301-------43.05-75.94-47.90-90.89-----1,428.87-2,386.13----0.00--237.44-1.8214.14--1.23--
Tetratherix Ltd73.38m-605.33m6.77bn----7.17--92.28-0.1873-0.18730.02270.54140.0688--2.22---56.71---76.72---172.06---824.89-----98.750.0697--32.30---269.05------
Island Pharmaceuticals Ltd3.78m-251.76m6.91bn----12.04--1,829.76-0.0224-0.02240.00030.03030.0117--0.1099---77.95-72.12-90.37-81.53-----6,666.91-19,239.15---162.890.00--1,148.41---36.86------
Take Solutions Ltd0.0036.61m7.03bn2.00188.0927.41190.60--0.25253.300.001.730.00----0.006.01-13.969.00-25.14--71.16---40.002.33-3.890.00---100.00--101.11------
Applied BioCode Corp1.28bn-599.91m7.14bn----3.60--5.57-2.11-2.114.456.690.38951.037.73---18.24-16.21-20.10-17.6758.1262.36-46.83-50.276.41--0.0833---13.1826.79-58.84---21.24--
Nano Holdings Inc92.44m-524.73m7.36bn20.00--4.50--79.57-12.46-12.462.1936.190.030844.495.297,817,050.00-17.51-23.68-22.01-25.3789.5482.69-567.67-746.835.93--0.4829---19.92-27.80-7.10------
Data as of Feb 18 2026. Currency figures normalised to Take Solutions Ltd's reporting currency: Indian Rupee INR
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.